A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T-Cell Lymphoma (TCL)

Type of Cancer

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T-Cell Lymphoma (TCL)

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.